Herschorn S1, McVary K2, Cambronero Santos J3, Foley S4, Kristy R5, Choudhury N6, Hairston J5, Kaplan S7
1.Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, 2.Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA, 3.Department of Urology, Infanta Leonor Hospital, Madrid, Spain, 4.Department of Urology, Royal Berkshire Hospital, Reading, UK, 5.Astellas Pharma Global Development Inc., Northbrook, IL, USA, 6.Astellas Pharma Europe Ltd., Chertsey, UK, 7.Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
Benign Prostatic Hyperplasia (BPH), Male, Overactive Bladder, Prospective Study, Clinical Trial